JNL/Invesco Small Cap Growth Fund

JNL Series Trust

Actively managed U.S. equity fund
$2.03B NAV
101 positions · as of 2026-06-30 · filed 2026-08-26

Fund classification

Classified from what the fund holds · as of 2026 Q2

JNL/Invesco Small Cap Growth Fund is an actively managed U.S. equity fund.

Asset class
Equity
Region
United States
Management
Actively managed
Fund type
Open-end fund

Fund profile

As filed in the prospectus · 2026 Q2

The investment objective of the Fund is long-term growth of capital.

Strategy · summarised

The fund invests at least 80% of its assets in common stock of small-capitalization companies with market capitalizations up to $28.02 billion as of December 31, 2025, and may hold up to 25% in foreign securities across developing and emerging markets, up to 20% in equities outside its core small-cap range, and up to 15% in real estate investment trusts. Because the fund's holdings depend on the manager's selection of individual securities rather than a defined index, performance will diverge from any benchmark.

Expenses
0.74% 1.04%across 2 share classes
Share classExpense ratioAs of
C0000046501.04%2025 Q2
C0000679810.74%2025 Q2

Portfolio turnover 86.00% · as of 2026 Q2

Allocation

Asset groups · long / short shown separately, never netted · 2026 Q2

100.81%
of net assets
Stocks96.57%
Cash & short-term4.24%

Sector allocation

The same holdings as Allocation above, grouped by market sector instead of asset type · as of 2026 Q2

100%
of net assets
Information Technology24.1%
Industrials21.7%
Health Care20.5%
International9.4%
8 smaller24.2%

Government, Securitized and Cash are non-corporate buckets; International is foreign holdings we don’t sector-classify, and Other is the residual (held funds, unresolved names).

Latest quarter

What changed since the fund's previous filing

2026Q2 vs 2026Q1: 24 new21 exited

Largest new: JFROG Ltd, Silicon Motion, Inc., VSH, CRL, PRAX, Kiniksa Pharmaceuticals International, PLC, RSI, KNX

Largest exited: Fabrinet, NXT, AR, RRR, Nvent Electric Public Limited Company, BE, OSIS, Ascendis Pharma A/S

Return profile

Total return as filed — price change plus distributions reinvested · trailing figures to Apr 2026

1-year
+41.31%
3-year
+55.16%
5-year
+3.08%
Volatility
17.99%
Worst 3-yr fall
-19.43%
Cumulative return· Jul 2023 – Apr 2026

May 2026 and Jun 2026 have been filed since the trailing figures were struck, so they are not in the table above or the curve — every figure here shares one cut-off, which is what makes them comparable with other funds.

This fund changed legal form during the period shown. The history above is continuous — it spans both eras, and the change is not a gap in reporting.

Holdings

By % of NAV · equity positions carry filed share counts · every resolvable issuer links to its company page

Issuer%NAVValue
JNL Government Money Market Fund3.54%$71.93M
MKS Inc.MKSI3.14%$63.75M
Brightspring Health Services, Inc.BTSG2.62%$53.25M
Allegro Microsystems Inc.ALGM2.56%$52.09M
ESCO Technologies Inc.ESE2.30%$46.78M
Sterling Infrastructure, Inc.STRL2.12%$42.97M
Lattice Semiconductor CorporationLSCC2.04%$41.45M
Sanmina CorporationSANM1.98%$40.24M
Axsome Therapeutics, Inc.AXSM1.97%$40.08M
Onto Innovation Inc.ONTO1.94%$39.35M
Showing 10 of 101Sign in to see more

Reported price is the fund's own reported value divided by its own reported shares at 2026-06-30 — not a live quote, and not what the fund paid.

Top 10 positions are 24.23% of net assets, top 25 48.79%, across 101 issuers.

See more of this fund's book

More positions with filed share counts, and the quarter-over-quarter change list rather than the largest few — free with an account, no card required.

Sign in free